On 9/4/24, Ascendis Pharma AS (NASDAQ: ASND) stock suffered a major decline of -11.3%, closing at $119.50. Moreover, this decline was accompanied by exceptionally high trading volume at 808% of normal. The stock has declined -13.7% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
ASND is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Ascendis Pharma AS is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment